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COVID Vaccine Hesitancy Statistics
• National Statistics as of December 2020, based on Kaiser Family Foundation’s Vaccine
tracker3:
• 27% of the public remains vaccine hesitant, saying they probably or definitely would
not get a COVID-19 vaccine even if it were available for free and deemed safe by
scientists
• Vaccine hesitancy is highest among Republicans (42%), those aged 30-49 (36%), and
rural residents (35%)
• 35% of Black adults say they definitely or probably would not get vaccinated, as do
one third of those who say they have been deemed essential workers (33%) and
three in ten (29%) of those who work in a health care delivery setting
• Reasons for hesitancy worries are due to possible side effects (59% cite this as a
major reason), lack of trust in the government to ensure the vaccines’ safety and
effectiveness (55%), concerns that the vaccine is too new (53%), and concerns over
the role of politics in the development process (51%)
• These statistics indicate a grave need for education over the efficacy and safety behind
mRNA vaccines

Public Health Costs of COVID Vaccination
• Based on data from the Kaiser Family Foundation7, Operation Warp Speed
and government funding is estimated at 10 billion dollars for COVID-19
vaccine research, development, and distribution
• Access to COVID-19 vaccines would be greatly enhanced if available at nocost to individuals or covered by insurance
• The federal government has taken steps to address this issue, with advance
purchasing of millions of doses of COVID-19 vaccines
• Legislative requirements have been passed to provide no-cost COVID-19
vaccines under private insurance, Medicaid, and Medicare
• Limitations and gaps remain - individuals may still face cost and barriers to
access for vaccination (Schwartz, Karen.)

Community Perspective
• Two interviews were conducted with local healthcare providers in
Brookfield, CT
• Both physicians expressed serious concern of COVID-19 vaccine
hesitancy in local community due to the rural setting of Brookfield
• Recent meeting with healthcare providers at Brookfield Family
practice cited additional concern for hesitancy among black patients
in surrounding community
• Distribution and access to vaccines remain a huge question
• Patient advocacy and education are potential solutions to address
problem

Intervention and Methodology
• Intervention: Educational handout was created to explain mRNA
vaccine technology, efficacy, and safety in lay terms for the general
public
• Methodology: Educational handout will be provided to patients in
clinic to address questions and concerns about the COVID-19 vaccine
• References for the handout clearly defined so that patients can
further read about the topic
• The goal is to help educate patients on the science behind mRNA
vaccines and hopefully reduce hesitancy about the vaccine in the
local Brookfield community

Results
• Handout presented to Brookfield Family practice providers
• Administrators plan on distributing handout throughout clinic for
patient education
• “Extremely pertinent and should be very helpful for patients who are
vaccine hesitant” - Primary Care Physician
• “I have concerns about vaccination hesitancy, especially among the
black community. Educational handouts, like this one, can help
reduce concerns and make a significant difference going forward” –
Primary Care Physician

Evaluation of effectiveness and limitations
• Initial review of the handout by providers at Brookfield Family Practice were
positive
• The team seemed enthusiastic to distribute the handout to patients who had
questions regarding the efficacy and safety of COVID-19 vaccines
• To evaluate for effectiveness of the handout:

• An initial survey would be created that would assess a patient’s overall hesitancy towards
the COVID-19 vaccine and reasons for their hesitancy
• A survey after reading the handout would evaluate patient understanding of mRNA vaccines,
and assess whether a patient’s hesitancy has changed or whether they are more willing to
receive a vaccine

• Implementation of a pre- and post-survey could not be accomplished during this
rotation, but would provide data to measure whether education on vaccines
affects hesitancy
• One limitation for this handout is the lack of data on long term efficacy and safety

Recommendations for future
interventions/projects
• Recommendations for future projects involving COVID-19 vaccination
would be to implement a quantitative assessment to examine
whether an educational handout could impact hesitancy
• A pre-and-post survey would be one possible quantitative
measurement
• Another potential future project would be to create an updated
version of an educational handout on COVID-19 vaccines with more
data on long-term efficacy and safety
• This potential idea would be important if there is a need for further
vaccination against COVID-19 in the future

References
• 1. Baden, Lindsey R., et al. “Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine: NEJM.” New England
Journal of Medicine, 30 Dec. 2020, www.nejm.org/doi/10.1056/NEJMoa2035389.
• 2. “Coronavirus (COVID-19) Frequently Asked Questions.” Centers for Disease Control and Prevention,
Centers for Disease Control and Prevention, 31 Dec. 2020, www.cdc.gov/coronavirus/2019-ncov/faq.html
• 3. Kirzinger, Ashley. “KFF COVID-19 Vaccine Monitor: December 2020.” Kaiser Family Foundation, 22 Dec.
2020, www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/.
• 4. “MERS Coronavirus Particle.” Middle East Respiratory Syndrome Coronavirus Particle, NIAID, 12 Feb. 2014.
https://search.creativecommons.org/photos/1139f382-1014-41d0-8d39-acd92807b382.
• 5. Najera, F. Rene. “What Is an MRNA Vaccine?” The History of Vaccines, College of Physicians of
Philadelphia, 10 Nov. 2020, historyofvaccines.blog/2020/07/29/what-is-an-mrna-vaccine/.
• 6. “Safety and Efficacy of the BNT162b2 Covid-19 Vaccine: NEJM.” New England Journal of Medicine, 10 Dec.
2020, www.nejm.org/do/10.1056/NEJMdo005933/full/.
• 7. Schwartz, Karen. “Vaccine Coverage, Pricing, and Reimbursement in the U.S.” Kaiser Family Foundation, 18
Nov. 2020, www.kff.org/coronavirus-covid-19/issue-brief/vaccine-coverage-pricing-and-reimbursement-inthe-u-s/.

